A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)
PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment
6
Participants
Timeline
Start Date
February 1, 2015
Primary Completion Date
March 14, 2019
Study Completion Date
March 14, 2019
Conditions
Limb-Girdle Muscular Dystrophy, Type 2D
Interventions
GENETIC
SRP-9004
Isolated Limb Infusion (ILI)
All Listed Sponsors
collaborator
Nationwide Children's Hospital
OTHER
lead
Sarepta Therapeutics, Inc.
INDUSTRY
NCT01976091 - A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D) | Biotech Hunter | Biotech Hunter